Bristol Myers to Acquire Karuna, a Neuroscience Drugmaker, for $14 Billion
Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna Therapeutics, which makes drugs to treat schizophrenia and Alzheimer’s, in an all-cash deal valued at $14 billion as it looks to strengthen its pipeline of neuroscience drugs. Bristol Myers said in a statement that it would pay $330 per share […]